LONDON, Nov. 24 /PRNewswire/ -- The European autoimmune disease diagnostics market has demonstrated sustained growth due to advances in detection technology and automation. Active consolidation is occurring in the market, promoting technology and product integration. However, the lack of clarity with regard to reimbursement policies for autoimmune diagnostic tests persists, posing a challenge to market expansion.
New analysis from Frost & Sullivan (http://www.drugdiscovery.frost.com), European Autoimmune Disease Diagnostics Market, finds that the market earned revenues of $513.5 million in 2008 and estimates this to reach $722.0 million in 2015.
"The development of novel biomarker panels has accelerated the diagnosis of many autoimmune complications," notes Frost & Sullivan Research Analyst Suraj Ramanathan. "Exhaustive R&D by many universities and research organisations has yielded promising results in the use of multiple biomarkers for autoimmune disease diagnosis."
The ability to screen a patient with multiple biomarkers associated with several autoimmune diseases has been shown to improve the accuracy of the diagnosis and has had a significant positive influence on the autoimmune disease diagnostics market. Such novel biomarker panels will continue to offer an added advantage to physicians in the diagnosis of these complications.
Despite the advances in detection technology, the generalised lack of awareness among the public with regard to autoimmune diseases presents a challenge to market growth.
"Such low levels of awareness may derive from the rarity of many
autoimmune complications among the general population," explains Ramanathan.
|SOURCE Frost & Sullivan|
Copyright©2008 PR Newswire.
All rights reserved